printer-friendly version (PDF) - Reflex Sympathetic Dystrophy ...

EMERGING TREATMENT AND DIAGNOSIS | MANNING
11. Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain.
Nat Rev Drug Discov. 2003; 2:973-985.
12. Weihe E, et al. Molecular anatomy of the neuroimmune connection. Int J
Neurosci. 1991; 59:1-23.
13. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional
immune-to-brain communication for understanding behavior,
mood, and cognition. Psychol Rev. 1998; 105:83-107.
14. Meyers C. Mood and cognitive disorders in cancer patients receiving
cytokine therapy. In: Dantzer R1 (Ed). Cytokines, Stress and Depression.
New York: Plenum. 1999, pp 75-82.
15. Balschun D, et al. Interleukin-6: a cytokine to forget. FASEB J. 2004;
18:1788-1790.
16. Ignatowski TA, et al. Brain-derived TNF-alpha mediates neuropathic pain.
Brain Res. 1999; 841:70-77.
17. Ignatowski TA, et al. Neuronal-associated tumor necrosis factor (TNF
alpha): its role in noradrenergic functioning and modification of its
expression following antidepressant drug administration. J Neuroimmunol.
1997; 79:84-90.
18. Huygen, FJ, et al. Mast cells are involved in inflammatory reactions during
complex regional pain syndrome type 1. Immunological Letters.
2004; 91:147-154.
19. Alexander, GM., et al. Changes in cerebrospinal fluid levels of pro-inflammatory
cytokines in CRPS. Pain; 116(3):213-219, 2005.
20. Hashizume H, Rutkowski MD, Weinstein JN, DeLeo JA. Central administration
of methotrexate reduces mechanical allodynia in an animal model
of radiculopathy/sciatica. Pain. 2000b; 87:159-169.
21. Sweitzer SM, DeLeo JA. The active metabolite of leflunomide, an
immunosuppressive agent, reduces mechanical sensitivity in a rat
mononeuropathy model. J Pain. 2002; 3:360-368.
22. Youssef S, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes
a Th2 bias and reverses paralysis in central nervous system autoimmune
disease. Nature. 2002; 420:78-84.
23. Menge T, Hartung HP, Stuve O. Statins-a cure-all for the brain? Nat Rev
Neurosci 2005; 6:325-331.
24. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate
inhibit the induction of nitric oxide synthase and cytokines in rat
primary astrocytes, microglia, and macrophages. J Clin Invest. 1997;
100:2671-2679.
25. Stuve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic
agents in neuroinflammatory disorders. Curr Opin Neurol. 2003;
16:393-401.
26. Perez J, et al. Dietary fat and protein interact in suppressing neuropathic
pain-related disorders following a partial sciatic ligation injury in rats.
Pain. 2004; 111:297-305.
27. Lehnardt S, et al. Activation of innate immunity in the CNS triggers nedegeneration
through a toll-like receptor 4-dependent pathway. Proc Natl
Acad Sci USA. 2003; 100:8514-8519.
28. Hwang D. Modulation of the expression of cyclo-oxygenase-2 by fatty
acids mediated through toll-like receptor 4-derived signaling pathways.
FASEB J. 2001; 15:2556-2564.
29. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not
unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated
through toll-like receptor 4. J Biol Chem. 2001; 276:16683-16689.
30. Weatherill AR, et al. Saturated and polyunsaturated fatty acids reciprocally
modulate dendritic cell functions mediated through TLR4. J
Immunol. 2005; 174:5390-5397.
31. Tanga FY, Nutile-McMenemy N, DeLeo JA. The CNS role of toll-like receptor
4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad
Sci USA. 2005; 102:5856-5861.
32. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side
effects of glucocorticoids. Pharmacol Ther. 2002; 96:23-43.
33. Karppinen J,et al. Tumor necrosis factor-alpha monoclonal antibody,
infliximab, used to manage severe sciatica. Spine. 2003; 28:750-753.
34. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the
treatment of acute, severe sciatica: a pilot study. Ann Rheum
Dis. 2004; 63:1120-1123.
35. Korhonen T, et.al. The treatment of disc herniation-induced sciatica with
infliximab: Results of a randomized, controlled, 3-month follow-up study.
Spine. 2005; 30: 2724-2728.
36. Huygen FJ, et.al. Successful treatment of CRPS-1 with anti-TNF. J Pain
Symptom Manage. 2004; 27:101-103.
37. Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1
receptor antagonists in human diseases. Ann Rheum Dis. 2002; 61:960-
967.
38. Corral LG, et al. Differential cytokine modulation and T-cell activation by
two distinct classes of thalidomide analogues that are potent inhibitors
of TNF-alpha. J Immunol. 1999; 163:380-386.
39. Peterson PK, et al. Thalidomide inhibits tumor necrosis factor-alpha production
by lipopolysaccharide- and lipoarabinomannan-stimulated
human microglial cells. J Infect Dis. 1995; 172:1137-1140.
40. Rajikumar, SV, et al. Complete resolution of reflex sympathetic dystrophy
with thalidomide treatment. Archives of Internal Medicine; 20:2502-
2503, 2001.
41. Prager J, et al. Open-label clinical experience of thalidomide in the treatment
of complex regional pain syndrome type I. The Journal of Pain;
4(2):68, 2003.
42. Schwartzman, R, et al. Open-label trial of thalidomide in the treatment of
complex regional pain syndrome type I. The Journal of Pain; 4(2):76,
2003.
43. Bengston K, et al. A phase II study of thalidomide in the treatment of
chronic complex region pain syndrome (CRPS). The Journal of Pain;
4(2):85, 2003.
44. Schwartzman R, et al. A multicenter, open-label, 12-week study with
extension to evaluate the safety and efficacy of lenalidomide (CC-5013)
in the treatment of complex regional pain syndrome type-1. pg 580 in:
Abstracts: 11th World Congress on Pain. IASP Press, Seattle. 2005.
DONALD C. MANNING,
MD, PhD, Executive Director,
Neurosciences Clinical
Research and Development
Celgene Corporation,
Summit, New Jersey
Clinical Associate Professor
of Anesthesiology and Pain
Management, University of
Virginia, Health Sciences
Center, Charlottesville, Virginia
62 | T H E PA I N P R A C T I T I O N E R | S P R I N G 2 0 0 6